Business Wire

TEMENOS

29.4.2020 08:32:10 CEST | Business Wire | Press release

Share
Temenos Launches New SaaS Propositions to Help Banks Respond to Covid-19 While Accelerating Their Digital Transformation

Temenos (SIX: TEMN), the banking software company, today announced the launch of eight propositions – using innovative Explainable AI (XAI) and cloud technologies – to help banks in their immediate response to the Covid-19 crisis. Temenos is supporting banks to ensure business continuity, enhance digital engagement to meet clients’ changing needs, and manage socioeconomic pressures. These Covid-19 propositions are immediately available worldwide. Delivered as Temenos SaaS, they are deployed quickly, easily and can be implemented remotely, if required.

Temenos is bringing together its dynamic community at Temenos Community Forum Online on 29-30 April to explore ‘Solutions for the New Normal’. Over 5,000 attendees have registered for the action-packed, virtual summit, with 43 product announcements, 49 live Q&A sessions with Temenos experts and over 30 demos showing Temenos’ latest innovations from cloud to digital engagement technologies and Explainable AI. At TCF Online Temenos will showcase how its solutions are addressing the fast-growing needs for digitalization, personalization and greater agility, solving the immediate Covid-19 challenges and creating sustainable business models for the future.

Max Chuard, Chief Executive Officer, Temenos, said: “I am proud of the AI and cloud-advanced propositions we have delivered to help banks address their most pressing needs during Covid-19. I am also proud of our family of Temenos employees, who have worked tirelessly to make this response a reality. As the leader in banking software, we are relentlessly investing in R&D to keep banks running as they assist SMEs, corporate and retail customers at a time of financial distress. In the ‘New Normal’, the need for modern digital banking will be greater than ever. Only Temenos can provide banks the richest banking functionality and the most advanced cloud-native technology to help them deliver value to their customers and build sustainable growth in the future.”

To support banks, Temenos launched the following AI-driven SaaS technology propositions which are immediately available to help banks with the Covid-19 crisis:

  • Enhancing customer digital interactions – With the surge in digital banking volumes Temenos is helping banks meet customers’ needs for intimate digital interactions, particularly those who typically bank in branches. Temenos Infinity Engage gives customers a personal digital communications channel to connect with their trusted advisors within the bank.
  • Helping banks give financial relief to SMEs and retail customers with Explainable AI (XAI)Temenos’ new XAI models delivered as SaaS help banks assist small businesses and retail customers with fast loan approval and viable financial products. These XAI models delivered as SaaS will help banks digitally on-board, conduct eligibility checks, process loan applications and establish the right product pricing. These models include Temenos AI - Urgent Relief Loan, Temenos AI-Personalization and Temenos AI – SME Smart Decisioning.
  • US Paycheck Protection Program quick roll out – Temenos is helping US banks and credit unions with Temenos Infinity, the digital omnichannel product, to rapidly process loan applications from small businesses under the US government’s PPP and give them the funding they need. Temenos working together as one team with Atlantic Union Bank helped the bank build a brand new digital loan portal specifically for PPP in less than a week.
  • Rapidly adapt AML, KYC and fraud management to new emerging threats – Temenos has partnered with Microsoft to offer fast access to its AI-driven, Temenos Financial Crime Mitigation SaaS solution to help banks combat the rise in cybercrime due to Covid-19. Temenos has proven its ability to support banks of all sizes without disruption, providing comprehensive AML/KYC/fraud management while all bank employees are working remotely.
  • Helping banks rapidly launch or adapt products to respond to Covid-19 – Governments and regulators are asking banks to make product changes, such as payments holidays and loan restructurings. Temenos Continuous Deployment delivered as Temenos SaaS supports banks to accelerate changes in test and live environments, providing remote, automated, secure DevOps tools. This means that all necessary product changes can take place in these fast changing, and resource constrained times.
  • Providing training opportunities for bank employees – Temenos opened its online learning platform with over 400 courses for all Temenos products and sandboxes for free to allow bank users to experience and test Temenos’ latest technology innovations from their own home. More than 3,000 banking practitioners have registered to increase their knowledge on Temenos products and upskill team members. To request free access by visit here .

– Ends –

About Temenos

Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 500 million banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.

Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business.

For more information, please visit www.temenos.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye